AR009673A1 - Forma en microparticulas del clorhidrato de 1-[2-(2-naftil)etil]-4-(3- trifluorometilfenil)-1,2,3,6-tetrahidropiridina y composiciones farmaceuticasque las contienen - Google Patents
Forma en microparticulas del clorhidrato de 1-[2-(2-naftil)etil]-4-(3- trifluorometilfenil)-1,2,3,6-tetrahidropiridina y composiciones farmaceuticasque las contienenInfo
- Publication number
- AR009673A1 AR009673A1 ARP970106030A ARP970106030A AR009673A1 AR 009673 A1 AR009673 A1 AR 009673A1 AR P970106030 A ARP970106030 A AR P970106030A AR P970106030 A ARP970106030 A AR P970106030A AR 009673 A1 AR009673 A1 AR 009673A1
- Authority
- AR
- Argentina
- Prior art keywords
- contain
- pharmaceutical compositions
- trifluorometilfenil
- tetrahidropiridina
- naftil
- Prior art date
Links
- 239000011859 microparticle Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- WVHBEIJGAINUBW-UHFFFAOYSA-N Xaliproden hydrochloride Chemical compound Cl.FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=C4C=CC=CC4=CC=3)CC=2)=C1 WVHBEIJGAINUBW-UHFFFAOYSA-N 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invencion se refiere a una forma de micropartículas del clorhidrato de 1-[2-(2-naftil)etil]-4-(3-trifluoro-metilfenil)-1,2,3,6-tetrahidropiridinacompuesta por partículas de las cuales por lo menos 55% del conjunto tiene un diámetro inferior a50 micrometros, y a las composiciones farmacéuticas que lacontienen.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9615905A FR2757510B1 (fr) | 1996-12-23 | 1996-12-23 | Forme microparticulaire d'un derive de tetrahydropyridine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR009673A1 true AR009673A1 (es) | 2000-04-26 |
Family
ID=9499044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970106030A AR009673A1 (es) | 1996-12-23 | 1997-12-19 | Forma en microparticulas del clorhidrato de 1-[2-(2-naftil)etil]-4-(3- trifluorometilfenil)-1,2,3,6-tetrahidropiridina y composiciones farmaceuticasque las contienen |
Country Status (37)
| Country | Link |
|---|---|
| US (4) | US20020028247A1 (es) |
| EP (1) | EP0950051B1 (es) |
| JP (2) | JP4422214B2 (es) |
| KR (1) | KR100455797B1 (es) |
| CN (1) | CN1088698C (es) |
| AR (1) | AR009673A1 (es) |
| AT (1) | ATE250032T1 (es) |
| AU (1) | AU730302B2 (es) |
| BR (1) | BR9714177A (es) |
| CA (1) | CA2275593C (es) |
| CO (1) | CO4920213A1 (es) |
| CZ (1) | CZ294272B6 (es) |
| DE (1) | DE69724999T2 (es) |
| DK (1) | DK0950051T3 (es) |
| DZ (1) | DZ2386A1 (es) |
| EE (1) | EE04112B1 (es) |
| EG (1) | EG24749A (es) |
| ES (1) | ES2207758T3 (es) |
| FR (1) | FR2757510B1 (es) |
| HU (1) | HU224348B1 (es) |
| IL (1) | IL129937A (es) |
| IN (1) | IN186977B (es) |
| IS (1) | IS2064B (es) |
| MY (1) | MY126298A (es) |
| NO (1) | NO311569B1 (es) |
| NZ (1) | NZ336129A (es) |
| PL (1) | PL190098B1 (es) |
| PT (1) | PT950051E (es) |
| RU (1) | RU2193031C2 (es) |
| SI (1) | SI0950051T1 (es) |
| SK (1) | SK283917B6 (es) |
| TR (1) | TR199901362T2 (es) |
| TW (1) | TW534820B (es) |
| UA (1) | UA66776C2 (es) |
| WO (1) | WO1998028272A1 (es) |
| YU (1) | YU49427B (es) |
| ZA (1) | ZA9711579B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101961317A (zh) * | 2001-07-06 | 2011-02-02 | 生命周期药物公司 | 受控制的凝聚 |
| BE1015641A4 (fr) * | 2003-05-26 | 2005-07-05 | Mariani Jean Paul | Micronisation 70. |
| RU2472490C1 (ru) * | 2011-08-05 | 2013-01-20 | Открытое акционерное общество "Биосинтез" | Средство для лечения кожных гнойных инфекций, составы и способы получения |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US562883A (en) * | 1896-06-30 | Thill-coupling | ||
| FR2531707A1 (fr) * | 1982-08-16 | 1984-02-17 | Midy Spa | Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques |
| US4826689A (en) * | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
| FR2627696B1 (fr) * | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | Nouvelle forme galenique du fenofibrate |
| FR2639226B1 (fr) * | 1988-11-18 | 1993-11-05 | Sanofi | Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs |
| FR2662355B1 (fr) * | 1990-05-22 | 1994-11-10 | Sanofi Sa | Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux. |
| ES2127835T3 (es) * | 1992-10-26 | 1999-05-01 | Sanol Arznei Schwarz Gmbh | Procedimiento para la preparacion de microcapsulas. |
| US5560932A (en) * | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
| US5662883A (en) * | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
| US6489334B2 (en) * | 1996-12-23 | 2002-12-03 | Sanofi-Synthelabo | Method for the crystallization of a tetrahydropyridin derivative and resulting crystalline forms |
| FR2763847B1 (fr) * | 1997-05-28 | 2003-06-06 | Sanofi Sa | Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1 |
| US20020147216A1 (en) * | 2000-01-31 | 2002-10-10 | Yuhong Zhou | Mucin synthesis inhibitors |
-
1996
- 1996-12-23 FR FR9615905A patent/FR2757510B1/fr not_active Expired - Fee Related
-
1997
- 1997-12-19 AR ARP970106030A patent/AR009673A1/es not_active Application Discontinuation
- 1997-12-22 DZ DZ970236A patent/DZ2386A1/xx active
- 1997-12-22 MY MYPI97006232A patent/MY126298A/en unknown
- 1997-12-23 NZ NZ336129A patent/NZ336129A/xx not_active IP Right Cessation
- 1997-12-23 PT PT97952987T patent/PT950051E/pt unknown
- 1997-12-23 DK DK97952987T patent/DK0950051T3/da active
- 1997-12-23 IL IL12993797A patent/IL129937A/en not_active IP Right Cessation
- 1997-12-23 CZ CZ19992291A patent/CZ294272B6/cs not_active IP Right Cessation
- 1997-12-23 EE EEP199900263A patent/EE04112B1/xx not_active IP Right Cessation
- 1997-12-23 YU YU28899A patent/YU49427B/sh unknown
- 1997-12-23 SK SK829-99A patent/SK283917B6/sk not_active IP Right Cessation
- 1997-12-23 KR KR10-1999-7005372A patent/KR100455797B1/ko not_active Expired - Fee Related
- 1997-12-23 RU RU99116321/04A patent/RU2193031C2/ru not_active IP Right Cessation
- 1997-12-23 SI SI9730592T patent/SI0950051T1/xx unknown
- 1997-12-23 HU HU0001181A patent/HU224348B1/hu not_active IP Right Cessation
- 1997-12-23 IN IN3767DE1997 patent/IN186977B/en unknown
- 1997-12-23 CN CN97180862A patent/CN1088698C/zh not_active Expired - Fee Related
- 1997-12-23 BR BR9714177-1A patent/BR9714177A/pt not_active Application Discontinuation
- 1997-12-23 CO CO97074790A patent/CO4920213A1/es unknown
- 1997-12-23 US US09/331,514 patent/US20020028247A1/en not_active Abandoned
- 1997-12-23 WO PCT/FR1997/002394 patent/WO1998028272A1/fr not_active Ceased
- 1997-12-23 ES ES97952987T patent/ES2207758T3/es not_active Expired - Lifetime
- 1997-12-23 EG EG138497A patent/EG24749A/xx active
- 1997-12-23 JP JP52848298A patent/JP4422214B2/ja not_active Expired - Fee Related
- 1997-12-23 AT AT97952987T patent/ATE250032T1/de active
- 1997-12-23 UA UA99063520A patent/UA66776C2/uk unknown
- 1997-12-23 EP EP97952987A patent/EP0950051B1/fr not_active Expired - Lifetime
- 1997-12-23 ZA ZA9711579A patent/ZA9711579B/xx unknown
- 1997-12-23 DE DE69724999T patent/DE69724999T2/de not_active Expired - Lifetime
- 1997-12-23 CA CA002275593A patent/CA2275593C/en not_active Expired - Fee Related
- 1997-12-23 TR TR1999/01362T patent/TR199901362T2/xx unknown
- 1997-12-23 AU AU56685/98A patent/AU730302B2/en not_active Ceased
- 1997-12-23 PL PL97334276A patent/PL190098B1/pl not_active IP Right Cessation
-
1998
- 1998-01-21 TW TW086119619A patent/TW534820B/zh not_active IP Right Cessation
-
1999
- 1999-06-10 IS IS5077A patent/IS2064B/xx unknown
- 1999-06-22 NO NO19993077A patent/NO311569B1/no not_active IP Right Cessation
-
2002
- 2002-06-21 US US10/177,384 patent/US20020192292A1/en not_active Abandoned
-
2008
- 2008-06-13 US US12/138,582 patent/US20080255365A1/en not_active Abandoned
-
2009
- 2009-06-10 JP JP2009139083A patent/JP2009280581A/ja active Pending
- 2009-10-05 US US12/573,455 patent/US20100021541A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR018197A1 (es) | Compuestos de piperidina, un procedimiento para su preparacion, una composicion y uso del mismo para la preparacion de un medicamento | |
| AR034737A1 (es) | Conjunto de elementos de desgaste | |
| BR9911724A (pt) | Ciclosporina que tem um perfil de atividade melhorado | |
| DZ2964A1 (fr) | Diphénylurées substituées nouvelles, et compositions pharmaceutiques les contenant. | |
| AR098808A2 (es) | Una forma de dosificación farmacéutica de fusión instantánea que se desintegrará en la boca en un tiempo de 25 segundos | |
| CY1108547T1 (el) | Αναλογα σωματοστατινης | |
| ECSP045239A (es) | Composicion de ziprasidona y controles sinteticos | |
| AU2003293405A8 (en) | Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5h-2,3-benzodiazepine and uses thereof | |
| FR2902974B1 (fr) | Inhibiteur d'endo-beta-1,4-xylanase et xylanases nouvelles, et produits alimentaires les contenant | |
| ATE359279T1 (de) | Moschus-geruchsstoffe | |
| EA200400280A1 (ru) | Новые неочищенные и кристаллические формы гидрохлорида лерканидипина | |
| MXPA03010158A (es) | Sulfonamidas. | |
| MY135916A (en) | Use of certain affinity nmda antagonists as antidepressants | |
| ATE381533T1 (de) | Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung | |
| DE60025639D1 (de) | Substituierte diazepan | |
| EP1457212A4 (en) | OPHTHALMIC DROPS | |
| IT1269185B (it) | Associazione dotata di effetto sinergico che ha un effetto antagonista dei recettori nk1 e nk2 | |
| AR009673A1 (es) | Forma en microparticulas del clorhidrato de 1-[2-(2-naftil)etil]-4-(3- trifluorometilfenil)-1,2,3,6-tetrahidropiridina y composiciones farmaceuticasque las contienen | |
| GT199800009A (es) | Forma en microparticulas del clorhidrato de 1-[2-(2-naftil)etil]-4-(3-trifluoro-metilfenil)-1,2,3,6-tetrahidropiridina. | |
| BR9910696A (pt) | Composições farmacêuticas | |
| ATE282417T1 (de) | Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen | |
| UY25247A1 (es) | Asociacion de principios activos para el tratamiento de la demencia senil de tipo alzheimer | |
| MXPA03001540A (es) | 4-fenil-1-(1-fienl-ciclohexil)-1,2,3,6-tetrahidro-piridina sustituida. | |
| AR011730A1 (es) | UNA FORMA FARMACÉUTICA DE CANTIDADES FIJAS DE UN INIHIBIDOR DE LA ENZIMA CONVERSORA DE ANGIOTENSINA Y DE UN ANTAGONISTA DEL CANAL DE CALCIO , COMPOSICIoN FARMACÉUTICAMENTE ACEPTABLE QUE COMPRENDE DICHA FORMA FARMACÉUTICA , PROCEDIMIENTO PARA LA OBTENCIoN DE DICHA COMPOSICIoN FARMACÉUTICAMENTE ACEPTA | |
| ATE282416T1 (de) | Die verwendung von nk-1 rezeptor antagonisten für die behandlung von substanz-verwendung störungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |